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Abstract: Prostate cancer (PCa) is a multifactorial disease characterized by the aberrant activity of
different regulatory pathways. STAT3 protein mediates some of these pathways and its activation is
implicated in the modulation of several metabolic enzymes. A bioinformatic analysis indicated a
STAT3 binding site in the upstream region of SHMT2 gene. We demonstrated that in LNCaP, PCa cells’
SHMT2 expression is upregulated by the JAK2/STAT3 canonical pathway upon IL-6 stimulation.
Activation of SHTM2 leads to a decrease in serine levels, pushing PKM2 towards the nuclear
compartment where it can activate STAT3 in a non-canonical fashion that in turn promotes a transient
shift toward anaerobic metabolism. These results were also confirmed on FFPE prostate tissue sections
at different Gleason scores. STAT3/SHMT2/PKM2 loop in LNCaP cells can modulate a metabolic shift
in response to inflammation at early stages of cancer progression, whereas a non-canonical STAT3
activation involving the STAT3/HIF-1α/PKM2 loop is responsible for the maintenance of Warburg
effect distinctive of more aggressive PCa cells. Chronic inflammation might thus prime the transition
of PCa cells towards more advanced stages, and SHMT2 could represent a missing factor to further
understand the molecular mechanisms responsible for the transition of prostate cancer towards a
more aggressive phenotype.
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1. Introduction
Prostate cancer (PCa) is a biologically heterogeneous disease, with great differences in its clinical
and histological features. The molecular basis of PCa pathogenesis and progression, in fact, is marked
by the aberrant activity of alternative regulatory pathways (IL-6, EGF, STAT3, PI3K, PTEN, AKT, mTOR,
MAPK) other than the androgen receptors (ARs) signaling [1]. In particular, these pathways are able to
interfere with cellular energy metabolism by redirecting glycolysis to lactate production, triggering the
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Warburg effect even in normoxia [2]. The establishment of the Warburg effect drives tumor cells to high
glucose consumption, a reduction in cellular respiration, and an increased synthesis of one-carbon
units [3] for the biosynthesis of nucleotides, proteins, and lipids, together with glutathione [4].
As result of this metabolic shift, PCa cells survive, even in the presence of a significantly increased
demand of precursors that occurs during uncontrolled proliferation. The requirement of higher energy
levels is supplied by a rise in oxidative phosphorylation that, in turn, could result in an increased and
harmful ROS production [5].
The protein STAT3 is a well-known oncoprotein and is considered a master regulator, and a
hub, of numerous signaling pathways. STAT3 mediates the signal transduction from the extracellular
environment into the nucleus by means of a canonical pathway that involves its phosphorylation
at Tyr705 (pY705-STAT3) in response to cytokine activation, growth factors, or other oncoproteins.
This specific modification triggers the formation of homodimers and their subsequent translocation
into the nucleus.
While its activation is rapid and transient in normal cells, STAT3 was found constitutively activated
as pY705-STAT3 in tumor cells, promoting an altered synthesis of key proteins responsible for the
onset and progression of carcinogenesis (BIRC5 and MCL1, anti-apoptotic proteins; P21 and c-MYC,
cell cycle regulators; VEGF, angiogenic factor) [6].
In addition to phosphorylation at Y705, STAT3 may present a diversified post-translational
modification (PTM) profile that is responsible for its pleiotropic biological functions. In particular,
the phosphorylation at Ser727 (pS727-STAT3) induces STAT3 localization to mitochondria, where it
can regulate the oxidative phosphorylation. pS727-STAT3, together with STAT3 glutathionylation at
residues Cys328 and Cys542 [7], seem to be related to an enhanced oxidative stress and associated
with a more advanced cancer form [8,9]. The involvement of STAT3 as a crossroad between signals
transduction and metabolism control could be mediated by both pY705-STAT3 and pS727-STAT3,
respectively referred to as canonical and non-canonical STAT3 pathways.
Recently, a STAT3-dependent induction and maintenance of the Warburg effect has been described
under hypoxia or oxidative stress conditions via activation of a STAT3/HIF-1α/PKM2 loop [10].
HIF-1α (Hypoxia Inducible Factor 1-α) is a transcription factor that acts as proteic sensor of hypoxia
and/or oxidative stress conditions [11,12]; PKM2 is a pyruvate kinase isoform expressed during
embryonic development, regeneration, and tumorigenesis [13] that catalyzes the conversion of
phosphoenolpyruvate to pyruvate with different efficacy depending on its quaternary state (tetrameric
or dimeric) [14].
It is conceivable to hypothesize that, in pathological or cancer staging events when these stress
conditions are not completely established (lower concentration of ROS and/or not hypoxia conditions),
the STAT3/HIF-1α/PKM2 axis may not be yet active [15]. However, cell growth and proliferation,
typical of tumor onset and progression, require a metabolic increase in order to satisfy the energy
demand. In these conditions, changes in the cellular pathways that link proliferation with metabolism
may be essential.
The Warburg effect is also related to an active one-carbon unit metabolism, primarily involving
the amino acid serine [16]. Serine biosynthesis is under the control of three cytosolic enzymes:
Phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first step of NAD+-dependent oxidation
of 3-phosphoglycerate (3PG) to 3-phosphohydroxypyruvate (3PHP); phosphoserine aminotransferase 1
(PSAT1), which converts 3PHP into 3-phosphoserine (3PS) by a glutamate-dependent transamination
reaction; and phosphoserine phosphatase (PSPH), which catalyzes the last step of the serine synthesis [17].
Additionally, serine hydroxymethyltransferase (SHMT) is responsible for serine metabolism [18].
In particular, the mitochondrial isoform SHMT2 catalyzes the cleavage of serine with the production of
glycine, essential for GSH and heme synthesis, and 5,10-methylentetrahydrofolate, a one-carbon unit
carrier indispensable for several anabolic pathways that include de novo nucleotide biosynthesis [19,20].
Among all the above-mentioned enzymes involved in serine metabolism, only SHMT2 has
revealed the presence of a STAT3 binding site in the promoter region of the gene, as proposed by
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bioinformatic analysis of DNA sequences and chromatin immunoprecipitation assay (BioGrid and [21]).
In mitochondria, SHMT2 is essential for: (i) The production of formylmethionyl-tRNAs, necessary for
proper translation of encoded proteins; (ii) the activity for the mitochondrial isoenzyme of thymidylate
synthase; and (iii) the delivery of glycine to delta-aminolevulinate synthase, the enzyme that starts the
heme synthesis. All these activities allow to assign to SHMT2 a key role in the mitochondrial energetic
metabolism [22].
Serine is also an allosteric positive regulator of PKM2 [23], stabilizing its tetrameric form.
The tetrameric enzyme catalyzes the conversion of phosphoenolpyruvate to pyruvate more actively
with respect to the dimeric PKM2; for this reason, the SHMT2-catalyzed conversion of serine to glycine,
that results in the dissociation of PKM2 into dimers leads to a slowdown in the glycolytic flux [24].
The aim of this paper was to investigate the interplay between STAT3, acting through canonical and
non-canonical pathways, and the metabolic partners SHMT2, PKM2, and HIF-1α in driving the energetic
metabolism shift that occurs in PCa evolution. For this purpose, we performed experiments on two
different prostate cancer cell lines, LNCaP (less aggressive) and DU145 (more aggressive). We extended
the observation to PCa formalin-fixed paraffin-embedded (FFPE) tissue sections obtained from total
prostatectomies. Collected specimens are characterized by a different Gleason score, ranging from 6 to
9. Gleason score 6 represents a well differentiated and less aggressive PCa, whereas Gleason score 9 is
representative of a more undifferentiated, aggressive, and less hormone-responsive cancer stage [25].
In both cell lines, STAT3 activation mode, the amount and distribution of PKM2, SHMT2, and HIF-1α
proteins, as well as the cellular metabolic conditions, were evaluated in the presence or absence of
IL-6-induced inflammation. Expression levels of PKM2, SHMT2, and HIF-1α, together with interleukin
6, were also analyzed utilizing normal and tumor FFPE tissues.
Obtained data may contribute to add a piece to the complex jigsaw puzzle of the molecular
mechanisms at the basis of PCa transition towards a more aggressive hormone insensitive stage.
2. Materials and methods
2.1. Gene and Promoter Analysis
The SHTM2 gene locus location (ENSG00000182199:[Chr12:57229327-57234935]) in the human
chromosome 12 (Human (Ensemble GRCh38.p12)) was obtained using the Ensembl Genome Browser
(http://www.ensembl.org/). The SHTM2 gene upstream region of 3123 bps was selected for the STAT3
transcription factor binding site (TFBS) analysis. The STAT3 transcription factor position frequency
matrix (PFM) (Matrix ID: MA0144.2,) was retrieved from Jaspar DB version 2018 (http://jaspar.genereg.
net/) [26]. The STAT3 PFM Jaspar derived sequence logo is represented in Figure 1 [27,28].
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The position probability matrix (PPM) was derived from PFM, dividing the former nucleotide
count by the number of the sequences by means of Equation (1) (Position probability matrix (PPM)).
PPMk, j =
1
N
N∑
i=1
I
(
Xi, j = k
)
(1)
Given a set X of N aligned sequences of length l, the elements of the PPM are calculated by
dividing the nucleotide count by the number of sequences (N) where i ∈ {1, . . . , N}, j ∈ {1, . . . , l}, k ∈ {A,
C, G, T}, and I (a = k) is an indicator function. Pseudocounts equal to 0.8 were applied to avoid matrix
null entries [29]. The PPM was converted in position weight matrix (PWM) through the log likelihood
calculation (Equation (2): Position weight matrix (PWM) definition) (Figure 2).
PWMk, j = log2
(PPMk, j
bk
)
(2)
The value bk represents the background probabilities used, calculated on whole chromosome 12
guanine-cytosine content percentage (CG: 40.8%) and k = {A: 0.296, C: 0.204, G: 0.204, T: 0.296}.
Cells 2019, 8, x FOR PEER REVIEW 4 of 19 
 
Figure 1. The STAT3 Jaspar matrix logo. The logo of the matrix STAT3 from the Jaspar database on 
which experiments have been done. 
The position probability matrix (PPM) was derived from PFM, dividing the former nucleotide 
count by the number of the sequences by means of (Equation (1): Position probability matrix (PPM).). 
𝑃𝑃𝑀௞,௝ ൌ
1
𝑁෍𝐼൫𝑋௜,௝ ൌ 𝑘൯
ே
௜ୀଵ
 (1) 
Given a set X of N aligned sequences of length l, the elements of the PPM are calculated by 
dividing the nucleotide count by the number of sequences (N) where i ∈ {1, …, N}, j ∈ {1, …, l}, k 
∈ {A, C, G, T}, and I (a = k) is an indicator function. Pseudocounts equal to 0.8 were applied to avoid 
matrix null entries [29]. The PPM was converted in position weight matrix (PWM) through the log 
likelihood calculation (Equation (2): Position weight matrix (PWM) definition.) (Figure 2). 
PWM௞,௝ ൌ lo𝑔ଶ ൬
PPM௞,௝
𝑏௞ ൰ (2) 
The value bk represents the background probabilities used, calculated on whole chromosome 12 
guanine-cytosine content percentage (CG: 40.8%) and k = {A: 0.296, C: 0.204, G: 0.204, T: 0.296}. 
 
Figure 2. Calculated position weight matrix (PWM) by means of Equation 2. 
2.2. Cell Cultures 
Human prostate carcinoma LNCaP and DU145 cell lines were obtained from ATCC. Cell lines 
were grown to 80% confluence at 37 °C and 5% CO2 in RPMI 1640 (Sigma-Aldrich, Milan, Italy) 
medium, added to with 1% sodium pyruvate, 10% fetal bovine serum, 2 mM glutamine, 100 µg/ml 
streptomycin and 100 U/ml penicillin. Cells were stimulated with 50 ng/ml IL-6 (ReliaTech GmbH, 
Wolfenbüttel, Germany, cat. 200-030) for 2, 4, and 6 h. In some experiments, cells were pre-treated 
overnight with 3 µM AZD-1480, a JAK2 inhibitor (Sigma-Aldrich, SML1505), and then treated for 1 
h with a higher AZD-1480 concentration (6 µM). Lastly, cells were stimulated by adding 50 ng/ml IL-
6 and AZD-1480 concentration was reduced to 4.5 µM. The co-treatment was carried out for 2, 4, and 
6 h. 
2.3. Protein Extraction and Immunoblotting Analysis 
Protein extraction and immunoblotting analysis were performed essentially according to 
Cocchiola et al. [9]. To obtain total protein extracts, cells cultured on 6-well plates in different 
experimental conditions were scraped, harvested by centrifugation, washed in PBS, and cell pellets 
immediately lysed in buffer (2% SDS, 20 mM Tris-hydrochloride pH 7.4, 2 M urea, 10% glycerol) 
added to with 2 mM sodium orthovanadate, 10 mM DTTm and a protease inhibitor cocktail diluted 
1:100 (Sigma-Aldrich). 
Nuclei were isolated from cell pellets using a hypotonic buffer (10 mM HEPES, 10 mM KCl, 1.5 
mM MgCl2, 0.5 mM DTT), added to with 0.05% Triton-X, 2 mM sodium orthovanadate, and a protease 
inhibitor cocktail diluted 1:100 (Sigma-Aldrich), harvested by centrifugation and washed in 
hypotonic buffer. Nuclei pellets were lysed to obtain nuclear protein extracts as described above for 
total protein extracts. 
Proteins resolved by SDS-PAGE 10% TGX FastCast Acrylamide gel (BioRad, Segrate, Italy) were 
transferred on polyvinylidene fluoride PVDF membranes (BioRad) using the Trans-Blot Turbo 
Transfer System (BioRad). The membranes were blocked with 3% w/v Albumin Bovine Serum BSA 
(Carl Roth, Milano, Italy, CAS No. 0163.4) in Tris-buffered saline, and incubated with a specific 
Figure 2. Calculate siti f ti (2).
2.2. Cell Cultures
Human prostate carcinoma LNCaP and DU145 cell lines were obtained from ATCC. Cell lines
were grown to 80% confluence at 37 ◦C and 5% CO2 in RP I 1640 (Sigma-Aldrich, Milan, Italy)
ediu , added to with 1% sodiu pyruvate, 10% fetal bovine seru , 2 gluta ine, 100 µg/mL
strepto ycin and 100 U/ L penicillin. Cells were stimulated with 50 ng/mL IL-6 (ReliaTech GmbH,
olfenbüttel, er any, cat. 200-030) for 2, 4, and 6 h. In so e experiments, cells were pre-treated
overnight ith 3 µ AZ -1480, a JAK2 inhibitor (Sig a- ldrich, S L1505), and then treated for 1 h
with a higher AZD-1480 concentration (6 µM). Lastly, cells were stimulated by adding 50 ng/ L I -6
and AZD-1480 concentration was reduced to 4.5 µM. The co-treatment was carried out for 2, 4, and 6 h.
2.3. Protein Extraction and Immunoblotting Analysis
Protein extraction and immunoblotting analysis were performed essentially according to Cocchiola
et al. [9]. To obtain total protein extracts, cells cultured on 6-well plates in different experimental
conditions were scraped, harvested by centrifugation, washed in PBS, and cell pellets immediately
lysed in buffer (2% SDS, 20 mM Tris-hydrochloride pH 7.4, 2 M urea, 10% glycerol) added to with 2 mM
sodium orthovanadate, 10 mM DTTm and a protease inhibitor cocktail diluted 1:100 (Sigma-Aldrich).
Nuclei were isolated from cell pellets using a hypotonic buffer (10 mM HEPES, 10 mM KCl,
1.5 mM MgCl2, 0.5 mM DTT), added to with 0.05% Triton-X, 2 mM sodium orthovanadate, and a
protease inhibitor c cktail diluted 1:100 (Sigma-Aldrich), harvest d by centrifugation and washed in
hypotonic buffer. Nuclei pellets were lysed to ob ain nuclear protein ex racts as described above for
total pr tein ex racts.
Proteins resolved by SDS-PAGE 10% TGX FastCast Acrylamide gel (BioRad, Segrate, Italy) were
transfe red on polyvinylidene fluoride PVDF membranes (BioRad) using the Trans-Blot Turbo Transfer
System (BioRad). The membranes were blocked with 3% w/v Albumin Bovine Serum BSA (Carl Roth,
Milano, Italy, CAS No. 0163.4) in Tris-buffered saline, and incubated with a specific primary antibody
fo 1 h. Membranes were then washed thr e times in BSA 2% w/v in TBS, and incubated for 1 h with the
appropriate alkaline phosphatase (Sigma-Aldrich, Milan, Italy cat. A3687 and A3688, dilution 1:5000)
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or peroxidase (Jackson Immuno Research, Pero, Italy, cat. 115-035-174 and 211-032-171, dilution 1:5000)
conjugated secondary antibody. The peroxidase signal was detected with ECL Fast Femto reagent
(Immunological Sciences, Rome, Italy,), acquired by Molecular ImagerR ChemiDoc™ MP System
(Bio-Rad) and the intensity of protein bands was quantified using the ImageLab Software. The alkaline
phosphatase signal was detected with BCIP/NBT reagents (Carl Roth, Milano, Italy, CAS No. 298-83-9
and 6578-06-9). β-actin (total extracts) or lamin (nuclear extracts) were used as a normalization protein.
The immunoblotting detection was carried out using anti-SHMT2 (Invitrogen, Life Technologies,
Monza, Italy, cat. PA5-32228, antibody dilution 1:5000), anti-PKM2 (Cell Signaling, Euroclone, Pero,
Italy, cat. D78A4, antibody dilution 1:1000), anti-HIF-1α (Invitrogen, cat. MA1-516, antibody dilution
1:2000), anti-pY705STAT3 (Cell Signaling, cat. D3A7, antibody dilution 1:2000), anti-pS727STAT3
antibody (Sigma-Aldrich, cat. SAB4300034, antibody dilution 1:1000), anti-β-actin (Sigma-Aldrich,
cat. A1978 clone AC-15, antibody dilution 1:5000), and anti-lamin A (Abcam, Cambridge, UK, cat.
AB26300, antibody dilution 1:1000) primary antibodies. At least three experimental replicates were
performed for each biological sample.
2.4. Mitochondria Staining
Mitochondria were stained with MitoTracker®Orange CMTMRos (Invitrogen, M7510) before
fixation, in accordance with the manufacturer’s instruction. Cells were incubated for 30 min with the
mitochondrial dye at final concentration of 190 nM in serum-free culture media, and then washed three
times in serum-free culture media before fixation and immunofluorescence analysis.
2.5. Immunofluorescence
Immunofluorescence analysis was performed essentially according to Cocchiola et al. [9].
Cultured cells were grown on coverslips and treated with IL-6 and AZD-1480 upon the same
aforementioned experimental conditions, but for only one-time point (4 h). Cells grown on coverslips
were washed with PBS, fixed with 4% formaldehyde for 15 min, and then rinsed with PBS. Cells were
permeabilized with cold methanol (−20◦C) for 5 min. After washing three times with PBS, the cells
were blocked overnight with 3% w/v BSA (Sigma-Aldrich) in PBS. Fixed cells were processed for
immunofluorescence staining to detect the localization of PKM2 and SHMT2 using anti-PKM2 (Cell
Signaling D78A4, dilution 1:100) and anti-SHMT2 (Invitrogen PA5-32228, dilution 1:200) as specific
primary antibodies diluted in PBS containing 2% w/v BSA for 1 h. Following three washes with PBS
added to with 0.05% Triton and 2% w/v BSA (PBS-T), cells were incubated for 1 h in the darkness with
an FITC-conjugated secondary antibody (Jackson Immunoresearch, Euroclone, Pero, Italy, AlexaFluor
488-conjugated, cat. 211-545-109, dilution 1:800). Cell nuclei were counterstained with 100 ng/mL
Hoechst 33,258 (Sigma Aldrich, cat. 94403) for 15 min. After washing with PBS-T, coverslips were
mounted on glass microscopy slides with Duolink™ Mounting Medium and examined with a confocal
fluorescence microscope (ZEISS LSM510META) using 60x oil immersion objective. Images were
acquired and analyzed by ZEN 2.5 software (ZEISS, Germany).
2.6. Determination of Lactic and Pyruvic Acids
Lactic acid and pyruvic acid were analyzed by GC–MS as methoxime/tertbutyldimethylsilyl
derivatives as previously described by Paik et al. [30]. GC-MS analyses were performed with an Agilent
6850A gas chromatograph coupled to a 5973N quadrupole mass selective detector (Agilent Technologies,
Palo Alto, CA, USA). Chromatographic separations were carried out with an Agilent HP5ms
fused-silica capillary column (30 m × 0.25 mm i.d.) coated with 5%-phenyl/95%-dimethylpolysiloxane
(film thickness 0.25 µm) as stationary phase, using helium as the carrier gas at a constant flow rate of
1.0 mL/min, splitless injection mode at a temperature of 280 ◦C, and the following column temperature
program: 70 ◦C (1 min) then to 300 ◦C at a rate of 20 ◦C/min and held for 10 min. The spectra were
obtained in the electron impact mode at 70 eV ionization energy (ion source 280 ◦C and ion source
vacuum 10−5 Torr). MS analysis was performed simultaneously in TIC (mass range scan from m/z 50
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to 600 at a rate of 0.42 scans s−1) and SIM mode. GC-SIM-MS analysis was performed selecting the
following ions: m/z 174 for pyruvate, m/z 261 for lactate, and m/z 239 for 3,4-dimethoxybenzoic acid
(internal standard). Results were normalized on cell number and expressed as fold change relative to
control samples.
2.7. Extraction of RNA and RT-PCR
Total RNA was extracted from treated cells using TRIzol reagent (Invitrogen, cat. 15596026) in
accordance with the manufacturer’s instructions. RNA was quantified spectrophotometrically and
its quality was assessed by 1.5% agarose gel electrophoresis and staining with ethidium bromide.
The reverse transcription was carried out by Thermo Scientific RevertAid First Strand cDNA Synthesis
Kit (Thermo Fisher Scientific, Life Technologies, Monza, Italy, cat. K1622) in accordance with the
manufacturer’s instructions. Gene expression was evaluated with specific primers for HIF-1α, β-actin,
PKM2, SHMT2 and PSA (all from Qiagen) using CFX Connect™ Real-Time PCR Detection System
(BioRad Laboratories) with a SYBR-Green fluorophore based real-time reaction (Brilliant SYBR Green
QPCR Master Mix, Thermo Fisher Scientific). Gene expression analysis was performed using CFX
Manager™ Real Time PCR Detection System Software, Version 3.1 (BioRad).
2.8. Determination GSH/GSSG
Reduced (GSH) and oxidized (GSSG) glutathione were measured by HPLC-UV. Briefly, LNCaP cell
pellets (1 × 106 cells) were suspended in 10% ice-cold TCA and centrifuged for 15 min at 9000× g.
The supernatant was collected and GSH and GSSG were measured by HPLC using a poroshell 120
EC-C18 column (3 × 150 mm, 2.7 µm) with UV detection at 215 nm. The mobile phase consisted of
two solvent systems (A: 0.1% trifluoroacetic acid in water, and B: 100% 0.1% trifluoroacetic acid in
water/acetonitrile 93:7) and the separation was achieved at a flow rate of 0.8 mL/min with the following
elution gradient: 0–3 min 100% A + 0% B, 3–10 min from 100% A to 100% B. In these chromatographic
conditions, retention times were 2.58 min and 7.01 min for GSH and GSSG, respectively.
2.9. Protein Extraction from FFPE Section and Immunoblotting
Protein extraction from FFPE section was carried out as previously described [8,31]. Briefly, under
appropriate conditions, tissue samples were sonicated and protein extracted for immunoblot analysis.
Proteins were resolved by 10% SDS-PAGE, transferred on PVDF membranes, and immunodetected.
All protocols were carried out as described above (see Proteins extraction and Immunoblotting).
β-actin was used as housekeeping protein to normalize the protein levels and for each protein the
tumor/control tissue abundance ratio was used for the analysis. The ratio tumor/control tissue values
were used to correct for possible inter-individual differences in protein abundance not related to
PCa [8]. Immunodetection on protein extracts from tissues with different Gleason score was carried
out using specific antibodies against PKM2 (Cell Signaling, cat. D78A4, antibody dilution 1:1000),
SHMT2 (Invitrogen, cat. PA5-32228, antibody dilution 1:5000), and HIF-1α (Invitrogen, cat. MA1-516,
antibody dilution 1:2000).
2.10. RNA Extraction from FFPE and RT-PCR
RNA was isolated from FFPE sections using PureLink FFPE Total RNA Isolation kit (Invitrogen,
cat. K156002), in accordance with the manufacturer’s instructions. RNA samples were quantified
spectrophotometrically and loaded onto 1.5% agarose gel to visualize the degree of RNA integrity.
The reverse transcription was carried out with Thermo Scientific RevertAid First Strand cDNA
Synthesis Kit (Thermo Fisher Scientific, cat. K1622) in accordance with the manufacturer’s instructions.
Gene expression was evaluated with specific primers for PKM2, SHMT2, HIF-1α, and IL-6 (all
from Qiagen) by a CFX Connect™ Real-Time PCR Detection System (BioRad Laboratories) using
a SYBR-Green fluorophore based real-time reaction (Brilliant SYBR Green QPCR Master Mix,
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Thermo Fisher Scientific). Gene expression analysis was performed using CFX Manager™ Real Time
PCR Detection System Software, Version 3.1 (BioRad).
2.11. Statistical Analysis
Experiments were performed at least three times and obtained results are presented as mean,
standard deviation (boxes), and min/max values (bars). Statistical analysis was performed with
GraphPad Prism 7.0 software (GraphPad Software, San Diego, CA, USA) using a Student’s t-test.
3. Results
The molecular basis of prostate cancer cell progression from a less aggressive to a more aggressive
phenotype has not yet been elucidated. In this paper, we analyzed two prostate cancer cell lines,
LNCaP and DU145, with different proliferative rates and aggressiveness. In particular, we focused on
the potential role of SHMT2 as a new player in the STAT3 signaling cascades involved in the distinctive
metabolic condition displayed by the considered cell lines.
3.1. Analysis of SHMT2 Promoter Region for Potential STAT3 Cis-Element Binding Sites
Both STAT3 canonical and non-canonical signaling pathways are involved in the development
and differentiation of several cancer types. As a transcriptional factor, STAT3 can drive the expression
program of a plethora of protein factors, some of which are essential for many metabolic pathways in
cancer cells. Among these factors, PKM2 and HIF-1α emerged as key players in energy metabolism by
regulating glycolysis and oxidative phosphorylation.
Since SHMT2 mitochondrial activity has been associated with the allosteric modulation of PKM2,
we explored whether this enzyme could be under the control of STAT3-mediated signaling, as assumed
by Castello et al. [21].
STAT3 transcription factor binding site (TFBS) analysis was performed on the entire putative
promoter region 3123 bp upstream of SHMT2 gene on human chromosome 12. The transcription factor
matrix (TFM) of STAT3, obtained from Jaspar DB 2018, was used to analyze the selected region for the
STAT3 cis elements identification [26–28]. A putative STAT3 cis-element motif (CTTCCCAGTAG) at
−807 bp upstream position from the start of SHMT2 gene was identified (Figure 3).
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SHMT2 gene.
3.2. STAT3 PTMs, SHMT2, PKM2, and HIF-1α Levels in LNCaP and DU145 Cell Lines
In a previous study, we demonstrated that cancer prostatic tissues from different oncological
patients exhibited a specific STAT3 post-transl tional modific tion pattern depending on the tumor
st g [8]. We also provided evidences of the role of STAT3 and its PTMs as drivers in the progressi n
of PCa in prostate cancer cells [9]. Here, t se data were further confirmed on cellular xt acts from
LNCaP and DU145 cell line analyzed by Western blot. Figure 4A shows that STAT3 protein is
constitutively activated (p-Y705) in DU145 cells, while it is hardly detectable in LNCaP ones. In DU145
ell , as previously observed [9], STAT3 is phosphorylat d at serine 727 and this specific modificatio
is related with a mitochondrial localization, suggesting an involvement of this signal protein in the
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energetic metabolism. Therefore, the level of SHMT2, PKM2, and HIF-1α proteins in both cell lines
were measured.
HIF-1α is constitutively present in DU145 cells, while it is barely detectable in LNCaP cells [32].
In normoxic conditions, HIF-1α is hydroxylated and degraded by the ubiquitin–proteasome system.
For this reason, the observed accumulation of HIF-1α in DU145 cells may be the result of an established
oxidative stress condition in which ROS can inhibit HIF-1α hydroxylation/degradation [33]. Also PKM2
shows a different expression level in the two cell lines, more abundant in DU145 cells when compared
to LNCaP ones (Figure 4B,C). This difference may be correlated to the higher level of HIF-1α in DU145
cells and to the potential cooperative role of the two proteins in controlling cell metabolism [34,35].
Western blotting analysis, carried out on total and nuclear extracts, highlights a different localization of
PKM2 between the two cell lines; in fact, it is mainly localized in the cytosol of LNCaP cells, whereas it
is primarily present in the nuclear compartment in DU145 cells (Figure 4D). This different spatial
distribution may be associated with the specific metabolic condition (aerobic glycolysis) of DU145
cells [36]. Expression level of SHMT2 shows an inverse trend, with a greater amount detectable in
LNCaP cells (Figure 4B,C).
On the basis of these data, it is possible to consider LNCaP and DU145 cells a robust model for PCa
progression, differing not only in their androgen sensitivity, aggressive behavior, and differentiation,
but also in energetic metabolic conditions that can, at least in part, explain the different aggressiveness
degree of these two cell lines.
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West rn blot analysis of total protein extracts from LNCaP a d DU145 cells. Samples were analyzed
for STAT3 phosphoryla ion, both Y705 and S727 (A), and SHMT2, PKM2, and HIF-1α amounts (B).
The experiment was repeated three times and a represe tative blot image is shown. (C) Quantification
by densitometric nalysis of SHMT2, PKM2, and HIF-1α immun blots. For each sample, pro eins were
quantified and v lues normalized against the β-actin level presents in the same s l and aken
as housekeeping control. Data were plotted as mean ± standard deviatio (SD) of three sep rate
experiment . Asterisks i dicate significant differences in protein amount between the two cell lin s
(*** p < 0.001). (D) Western blotti g analysis of total a d nuclear protein xtracts from LNCaP and
DU145 cells analyzed for PKM2. Lamin was used as specific nuclear marker and normalization protein.
3.3. Effect of Cytokines Treatment on STAT3 PTMs, SHMT2, PKM2, and HIF-1α Levels
We investigated the different responsiveness of LNCaP and DU145 cells to inflammatory conditions
that are able to activate the JAK/STAT signaling.
Both cells lines were subjected to stimulation with the cytokine IL-6, which leads to STAT3
phosphorylation at tyrosine 705 via JAK2 receptor activation. Cells were treated with IL-6 in the
presence or not of AZD1480, a specific JAK2 inhibitor [37], and protein extracts were analyzed at 2,
4, and 6 h by Western blot and RT-PCR. STAT3 phosphorylation (pY705 and pS727), SHMT2, PKM2,
and HIF-1α levels were analyzed following the time-course.
Western blot analysis of STAT3 phosphorylation is reported in Figure 5A. The level of pY705-STAT3
showed a rapid increase at 2–4 h, whereas was found reduced at 6 h in parallel with the occurrence
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of serine 727 phosphorylation (pS727-STAT3). As expected, these modifications were absent in the
presence of the JAK2 inhibitor. This finding can be explained by the fact that pS727-STAT3, generally
associated with an oxidative stress condition, appeared as a result of an increase in ROS production
caused by the persistence of inflammation [38]. To address this point, the GSH/GSSG ratio was
evaluated as a marker for oxidative stress; obtained data show a clear decrease of the GSH/GSSG ratio
in LNCaP cells after 6 h of IL-6 treatment, while this is less evident in the presence of the JAK2 inhibitor
(Table 1). Therefore, pS727-STAT3 increase could be the result of a prolonged stimulation that induces
a pro-oxidative condition in the cell.
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Table 1. GSH and GSSG content measured in LNCaP cells subjected to different treatments.
Treatment GSH (nmol) GSSG (nmol) GSH/GSSG Ratio
Control (2 h) 36.74 6.86 5.36
IL6 (2 h) 33.37 6.72 4.97
IL6 + AZD1480 (2 h) 32.67 6.35 5.15
Control (6 h) 35.18 6.14 5.73
IL6 (6 h) 24,38 10.39 2.35
IL6 + AZD1480 (6 h) 24.80 6.00 4.13
Cells 2019, 8, 1048 10 of 20
Western blot analysis of SHMT2, PKM2, and HIF-1α levels is reported in Figure 5B. SHMT2 levels
are significantly higher at 4 h of IL-6 treatment, but are drastically reduced in the presence of AZD1480,
demonstrating that in LNCaP cells, the expression of SHMT2 is under STAT3 control through the
IL6/JAK2 pathway (Figure 5B,C). No detectable signal for HIF-1α was observed by Western blot in
un-stimulated LNCaP cells. In addition, PKM2 and HIF-1α do not show any significant variation after
IL-6 stimulation, both in the presence or absence of the inhibitor AZD1480.
RT-PCR analysis, performed on the same experimental samples, confirmed data obtained by
Western blot for PKM2 and SHMT2 (Figure 5D). Conversely, RT-PCR analysis showed a constant
transcription level of HIF-1α mRNA; the absence of a corresponding protein signal in Western blot
analysis is probably due to its degradation under normoxic conditions [39]. The mRNA level of PSA,
a PCa marker gene which expression is under control of IL-6/JAK2/STAT3 pathway [40], was included
in the RT-PCR analysis as positive control (Figure 5D).
Differently from LNCaP cells, pY705-STAT3 and pS727-STAT3 were already detectable in the
un-stimulated DU145 cells, remaining almost unaltered after IL-6 stimulation, both in presence or
absence of AZD1480 (Figure 6A). This evidence could probably be related to a constitutive activation of
STAT3 in DU145 cells. The amount of SHMT2, PKM2 and HIF-1α did not show significant variations
in all conditions at the analyzed time intervals (Figure 6B,C).
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extracts in a time cours experiment on DU145 cells, t t it IL-6 in presence or absence of a JAK2
inhibitor (AZD-1480). Samples wer analyzed for STAT3 phosphorylation, both Y705 and S727 (A),
and SHMT2, PKM2, and HIF-1α (B). The experiment was repeated three times and a representative
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experiments. (D) RT-PCR analysis of PKM2, SHMT2, HIF-1α, and CDC25A expression levels in DU145
cells after 4 h of IL-6 stimulation. The expression values were normalized to housekeeping gene
(β-actin) and expression level of untreated cells has been set to 1. Each value is the average of three
experiments ± SD.
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Results obtained by RT-PCR (Figure 6D) are consistent with those highlighted by Western blot
analysis and, differently from LNCaP cells, SHMT2 expression in DU145 cells did not seem to be under
IL6/JAK2/STAT3 pathway control. Considering that DU145 cells do not express PSA [41], CDC25A
was selected as reference gene under control of the IL-6/JAK2/STAT3 pathway [42].
3.4. Cellular Redistribution of SHMT2 and PKM2 Following IL-6 Stimulation
To assess the cellular localization of SHMT2 and PKM2 after cytokine stimulus, immunofluorescence
staining was performed on both LNCaP and DU145 cells. The protein SHMT2 showed a clear increase
in the mitochondrial compartment distribution of LNCaP cells upon IL-6 treatment, not detectable
in co-treatment with the JAK2 inhibitor (Figure 7A). This finding is consistent with the observed
intensification in SHMT2 signal upon IL-6 stimulation, reported above by Western blot and RT-PCR
analyses (Figure 5B–D). On the other hand, no appreciable variation in SHMT2 localization and signal
intensity was observed in DU145 cells after IL-6 stimulation, both in the absence or the presence of the
JAK2 inhibitor (Figure 7B).
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Figure 7. Cellular redistribution of SHMT2 and PKM2 following IL-6 stimulation. Immunofluorescence
analysis of SHMT2 (A,B) and PKM2 (C,D) proteins in LNCaP and DU145 cells after 4 h of IL-6
sti ulation, with or without a Jak2 inhibitor (AZD1480). (A, ) LNCaP cell line. (B,D) DU145 cell line.
The images were captured with a confocal fluorescence microscope (ZEISS LSM510META) using 60x
oil immersion objective (scale bar 10 µm).
Furthermore, in LNCaP cells the protein PKM2, mainly localized in the cytosol, underwent a
clear cellular localization within the nuclear compartment after 4 h of treatment with IL-6 (Figure 7C).
This behavior was noy observed in the presence of the JAK2 inhibitor (Figure 7C). On the contrary,
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the PKM2 cellular distribution in DU145 cells remained unaltered after stimulation, with a little nuclear
localization even under basal conditions (Figure 7D).
Western blot analysis was also performed on nuclear extracts from LNCaP and DU145 to further
follow variations in PKM2 cellular distributions (Figure 8). The nuclear localization of PKM2 was
confirmed in LNCaP cells after IL-6 stimulation and was not detectable in samples pre-treated with
the JAK2 inhibitor. On the other hand, the nuclear amount of PKM2 in DU145 cells seemed not to be
affected by treatments with both IL6 or AZD1480 (Figure 8).
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3.5. Lactate/Piruvate Extracellular Ratio in Lncap and DU145 Cell Lines
The increased amount of SHMT2 and its presence in the mitochondrial compartment of LNCaP
cells upon IL-6 stimulation, together with the nuclear localization of PKM2, led us to evaluate the
metabolic state of this cell line in response to IL-6 treatment.
For this purpose, pyruvate and lactate extracellular levels were analyzed, showing a remarkable
increase of the lactate/pyruvate ratio in the culture medium after 4 h of IL-6 stimulation (Table 2).
Table 2. Effect of IL-6 stimulation, in presence or absence of AZD1480, on the lactate/pyruvate ratio in
the medium of LNCaP and DU145 cells.
Time Cells Medium
Lactate/Pyruvate Ratio
LNCaP Cells DU145 Cells
2 h
Control 4.98 10.52
IL6 14.59 11.05
IL6+ AZD1480 6.12 ND
4 h
Control 4.86 11.34
IL6 21.27 10.94
IL6+ AZD1480 5.09 ND
6 h
Control 7.54 11.75
IL6 15.61 11.87
IL6+ AZD1480 9.42 ND
(ND, not determined).
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Conversely, this increase did not occur when cells were pre-treated with the JAK2 inhibitor.
These results suggest that a metabolic shift towards the Warburg effect took place in LNCaP cells
following IL-6 stimulation, probably driven by changes in SHMT2 and PKM2 status.
These variations include a STAT3-dependent increment in SHMT2 level, along with the nuclear
translocation of PKM2. The metabolic shift is transient, since after 6 h of IL-6 stimulation, SHMT2 protein
level is reduced, as well as the lactate/pyruvate ratio (Table 2). At the same time, PKM2 goes back
to being predominantly cytosolic (Figure 9). This IL-6-dependent metabolic shift is absent in DU145
cells, where the Warburg effect is probably maintained through the HIF-1α/PKM2/STAT3 axis [10],
further confirming the distinctive response to the inflammatory cytokine of these two differently staged
tumor cell lines.
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3.6. Expression of SHMT2, PKM2, and HIF-1α in Prostate Cancer FFPE (Gleason 6 and 9)
We evaluated the expression levels of SHMT2, PKM2, and HIF-1α in prostate cancer tissues
with different Gleason scores collected from human patients. Tissue specimens with a lower Gleason
score (G6) were compared with those with a higher Gleason score (G9), each corresponding to a
different degree of malignancy. Our previous data [8] showed a correlation between different STAT3
PTMs and the various Gleason scores. In particular, while pY705-STAT3 is present in both G6 and
G9 tissue, STAT3 is acetylated only in G6 samples, whereas is glutathionylated and phosphorylated
at Serine 727 only in G9 ones [8]. These modifications correlated with a different expression pattern
of STAT3-dependent genes. While in G6 samples, STAT3-dependent expressed genes are related to
inflammation processes, in G9, expressed genes are associated with the response to oxidative stress
and the presence of metastasis [8]. According to this information, it is possible to associate G6 and G9
grades to LNCaP and DU145 cells, respectively [43].
SHMT2, PKM2 and HIF-1α levels were analyzed in 63 FFPE samples, corresponding to the same
tissue samples used in our previous study [8]. Western blot analysis confirmed that SHMT2 is more
expressed in G6 tissues, while PKM2 in G9 ones; HIF-1α is increased only in G9 samples (Figure 10A).
To verify that the observed different protein levels could be related to a different inflammatory state
(IL-6 mediated), the mRNA level of this cytokine was analyzed in the same tissue samples. RT-PCR
results confirmed a higher expression of IL-6 in G6 samples that could be related to an inflammatory
condition and the subsequent activation the JAK2/STAT3 pathway (Figure 10B).
It is noteworthy that, differently from the in vitro model where LNCaP cells were subjected
to an acute and transient inflammation, G6 tissues are probably characterized by a chronic
inflammation. This condition could constitute the breeding ground for the evolution of prostate cancer
towards a more aggressive form (G9), involving a change in SHMT2 and PKM2 status through the
IL-6/JAK2/STAT3 pathway.
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Western blot analysis of protein extracted from FFPE corresponding to Gleason scores 6 (G6) and 9 (G9).
T: Prostate carcinomas; N: Normal tissue, adjacent to tumor. Densitometric analysis of cumulative
immunoblotting results of SHMT2, PKM2, and HIF-1α amount in tumor prostate tissues from 28
matched prostate carcinomas. Values are presented as means, standard deviations (boxes), and min/max
values (bars). (B) Quantitative RT-PCR expression analysis of IL-6, SHMT2, PKM2, and HIF-1α genes
in FFPE tissues with different Gleason scores (G6 and G9). Each gene expression value was normalized
to housekeeping gene (β-actin) and to a control sample (normal matching tissue). Values are presented
as means, standard deviations (boxes), and min/max values (bars).
4. Discussion
STAT3 is an oncoprotein involved in multiple regulatory pathways and could represent a crossroad
between signal transduction and metabolism control. Given its multitasking nature, STAT3 could be
responsible for the induction and maintenance of the Warburg effect under hypoxia or oxidative stress
conditions. In particular, STAT3 marks the different aggressiveness features of LNCaP and DU145
cancer cells through its canonical and non-canonical activation pathways, respectively.
In LNCaP, STAT3 phosphorylation at Y705 occurs only after IL-6 stimulation, while in DU145 it is
constitutively phosphorylated at Y705, with a prevalent nuclear localization. In addition, STAT3 is
already localized within mitochondria in un-treated DU145 by means of its phosphorylation at S727.
Therefore, IL-6 treatment appears not to affect the phosphorylation pattern of STAT3 in DU145,
whereas in LNCaP cells IL-6 triggers the canonical JAK2/STAT3 pathway. The constitutive activation
of STAT3 is a common denominator of several cancer types such as breast, lung, neck, and colon
cancer and melanoma [44], and it is established by non-canonical pathways of STAT3 activation.
These alternative pathways are mirrored by a different expression of STAT3-dependent proteins that
are involved in the modulation of energetic flux. SHMT2 was found to be over-expressed in LNCaP
upon IL-6 stimulation, while HIF-1α was detected as a constitutive factor in DU145 cells.
A metabolic control circuit involving STAT3, HIF-1α, and PKM2, previously described under
hypoxia and oxidative stress, seems responsible for the induction and maintenance of the Warburg
effect [10]. In this loop, STAT3 activation through its non-canonical pathway primes the expression of
HIF-1α, stabilized by the concomitant raising of ROS. In turn, HIF-1α behaves as a transcription factor,
enhancing cellular copies of PKM2; then, the nuclear translocation of PKM2 is able to phosphorylate
STAT3, thus maintaining the loop active. In DU145 cells, a constitutive presence of HIF-1α and a
nuclear localization of PKM2 were observed (Figures 7D and 8). These findings, along with the
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non-canonical activation of STAT3, strongly suggest that a similar loop took place in DU145: In fact,
this metabolic set-up could explain the increase in lactate production exhibited by this prostate cancer
line, according to the Warburg effect hallmarks (Table 2).
These cellular conditions represent the metabolic signature of the more aggressive phenotype
displayed by DU145 cells. On the contrary, LNCaP cell line, representative of the less aggressive
phenotype among prostate cancer subtypes, neither showed the constitutive presence of HIF-1α protein
nor the localization of PKM2 in the nuclear compartment. These outcomes indicate the absence of the
Warburg effect as a constitutive metabolic state in LNCaP cells.
However, during inflammation induced by IL-6, LNCaP presented a clear increase in lactate
production, indicating a metabolic shift toward the Warburg effect. In addition, we observed that the
activation of the JAK2/STAT3 pathway by IL-6 led to an increased mitochondrial expression of SHMT2.
This is probably due to the interaction of pY705-STAT3 with a specific nucleotide sequence of SHMT2
gene promoter, as assessed by bioinformatic analysis.
SHMT2 is at the crossroad of important pathways inside the mitochondrial matrix and its
relationship with higher lactate amount in the medium of LNCaP cells treated with IL-6 could be
explained by the effect of SHMT2 enzymatic activity in regulating PKM2 [45].
As stated above, serine, the substrate of SHMT2, is an allosteric positive regulator of PKM2
and stabilizes the tetrameric cytosolic form of the enzyme, which is involved in the glycolytic
pathway. A drop of serine concentration, due to an augmented SHMT2 activity as consequence of its
over-expression, favors the transition of PKM2 from the tetrameric to the dimeric form. This conversion
slows the glycolytic flux and increases the lactate/pyruvate ratio, resulting in the observed metabolic
shift. Furthermore, the dimeric form of PKM2 can translocate into the nuclear compartment, where it can
behave either as a protein kinase or as a transcriptional co-activator [46]. Hence, during inflammatory
conditions, STAT3 could activate a pathway involving SHMT2 and PKM2. In this protein axis,
PKM2 nuclear activity is regulated by STAT3 via SHMT2 in a HIF-1α-independent manner. Thus,
a different and new loop implicating STAT3/SHMT2/PKM2, instead of STAT3/HIF-1α/PKM2, can be
active under inflammatory conditions, leading to a metabolic shift (Figure 11). This metabolic set-up is
sustained by an increased expression of SHMT2, whose importance in the mitochondrial energetic
metabolism has been very recently reported [19].
In addition, the role of SHMT2 in tumor progression has been previously described for various
types of cancer such as colorectal cancer [47], intrahepatic cholangiocarcinoma [48], and glioma [49,50].
In glioma cells, SHMT2 is responsible for the Warburg effect by limiting the activity of PKM2,
thus conferring an advantage to these cancer cells in a poorly vascularized environment [45]. In LNCaP
cells, after IL-6 stimulation, the rise of SHMT2 observed after 4 h can affect the structure/activity of
PKM2, resulting in both the Warburg effect and the translocation of this enzyme towards the nuclear
compartment, where it can activate STAT3 through the non-canonical pathway.
Inflammation induced by IL-6 could alert cells, predisposing them to a metabolic shift towards
a Warburg-like state where the STAT3/SHMT2/PKM2 loop may be active. This is a more favorable
metabolic condition for cellular proliferation, because one-carbon units, useful for the anabolic
pathways, are guaranteed. At the same time, a slowdown in oxidative phosphorylation occurs,
thus reducing ROS production. This condition could be transient or constitutive and it depends on the
prolongation of the inflammation state, as well as the accumulation of ROS species.
An overall inflammatory state can lead to oxidative stress conditions that trigger HIF-1α-mediated
response. These intracellular events result in higher PKM2 levels, causing a subsequent metabolic
switch to altered glycolysis.
Upon these new cellular conditions that include hypoxia or oxidative stress, the already described
STAT3/HIF-1α/PKM2 loop is responsible for the induction and maintenance of the Warburg effect.
Taken together, the increase of HIF-1, the PKM2 transition towards the dimeric form, and the
non-canonical activation of STAT3 may account for the establishment of the circuit involving these
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protein players. This situation leads to a metabolic asset resembling that of the more aggressive prostate
cancer cells.
PKM2 and SHMT2 levels can play an important role in regulating the metabolic switch and
tumor progression. The evaluation of prostate cancer tumor tissues with Gleason scores of 6 and 9
confirmed the trend in the expression levels of SHMT2 and PKM2, and the alternative phosphorylation
of STAT3 already found in the two cell lines utilized in this study. In fact, under inflammatory
conditions (such as observable in Gleason 6 samples), PKM2 level remains low [51]. This finding
could limit PKM2 nuclear distribution, decreasing its ability to phosphorylate nuclear STAT3 and,
consequently, reducing STAT3 transcriptional activity. In this condition, the canonical JAK2/STAT3
pathway regulates the expression of SHMT2 that, through its enzymatic activity, is able to maintain
the redox homeostasis, reducing the glycolytic flow to oxidative phosphorylation, and to supply cell
metabolism with biosynthetic precursors. A protein loop involving STAT3/SHMT2/PKM2 can be active
at this cell stage (Figure 11), similarly to what observed in LNCaP cells stimulated with IL-6.
A prolonged inflammatory state leads to an increase of HIF-1α that can act as a transcriptional
factor for the expression of PKM2. In this vicious loop, the PKM2 levels progressively increase,
leading to a stimulation of the glycolytic pathway and the consequent ROS production. The cell enters
into an oxidative stress condition, which further contributes to increase HIF-1α levels, perpetuating
the conditions described above until a switch towards a stabilized anaerobic glycolysis occurs
(STAT3/HIF-1α/PKM2 loop) (Figure 11).
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The proposed new protein loop involving STAT3/SHMT2/PKM2 upon inflammatory conditions
was compared with the already described STAT3/HIF-1α/PKM2 feed forward loop [10]. SHMT2,
whose expression is under the IL6/JAK2/STAT3 pathway control, starts the feedback between nuclear
PKM2 and STAT3. The proposed STAT3/SHMT2/PKM2 forward loop occurs in hormone responsive
LNCaP cells but is lost in hormone-resistant DU145 cells.
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PKM2 and HIF-1α levels are highly increased in Gleason 9 samples, as well as pS727-STAT3,
which is a hallmark for oxidative stressing conditions. HIF-1α was not found to be present in Gleason
6 samples, despite the higher expression of IL-6, indicating a chronic inflammation observed in these
tissues. This discrepancy could be explained considering the more complex environment of a tissue
with respect to a cellular culture, where adverse effects induced by inflammatory processes, as well as
oxidative stress, may be more steadily counteract. Thus, if the inflammatory conditions remain at a
low level, the STAT3-dependent increase in SHMT2 cellular levels could lead to a metabolic condition
that allows both the cell growth and the reduction of free radical species [52]. Under these conditions,
only PKM2 cellular distribution is altered. We could hypothesize an interplay between SHMT2 and
PKM2 expression and intracellular activity. In fact, the prevalence of SHMT2 compared to PKM2
will keep the cell in a pre-alarm condition, while higher levels of PKM2 will lead the cell to change
permanently its metabolic state.
In conclusion, in this report, we addressed our attention to the potential new role of SHMT2 as
modulator of STAT3 signaling pathways. In particular, SHMT2 seems to be involved in STAT3 function
as master regulator of energy metabolism.
Given its key part in energy metabolism and its link to the protein STAT3, SHMT2 could represent
a missing piece to further understand the molecular mechanisms responsible for the transition of
prostate cancer towards a more aggressive phenotype.
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